On November 6, Caris Life Sciences, Inc. fell 5.11% in Regular Trading, trading at $24.61 per share, with turnover of $45.93 million.
The move followed continued post-earnings pressure after the company reported third-quarter results that exceeded market expectations on both revenue and earnings, but showed a year-over-year decline in EPS.
Caris Life Sciences, Inc. reported third-quarter revenue of $275.4 million, up from $216.8 million a year earlier and above consensus expectations of about $255.4 million. EPS came in at $0.05, above expectations of $0.03 to $0.04, but down from $0.08 in the prior-year period. The company also raised full-year revenue guidance to $1.04 billion to $1.05 billion from $1.03 billion to $1.04 billion previously. Even so, the stock had already fallen in after-hours trading following the release, and the latest session suggests that pressure has continued.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments